Revamped Cancer Drugs Fund Means More Positive Recommendations, Says NICE
Executive Summary
NICE, the health technology appraisal body for England and Wales, has rejected criticism that access to cancer drugs is worsening in the UK. The institute pointed to the revamped Cancer Drugs Fund which it said meant more positive recommendations.
You may also be interested in...
Getting Worse Not Better: UK Report On Access To Cancer Drugs
A UK report on patient access to cancer drugs suggests that the European Medicines Agency could learn from the US Food and Drug Administration and best practice elsewhere in the world when it comes to taking a faster, more flexible approach to assessing evidence.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.